Dr. Reddy’s Signs License Deal for Once-Yearly Lenacapavir
The Story:
Dr. Reddy’s has signed a royalty-free, non-exclusive license agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV PrEP, covering manufacturing readiness and future supply across 120 high-incidence countries.
The Take:
The agreement strengthens Dr. Reddy’s HIV portfolio and positions the company to support broader access to long-acting PrEP if the once-yearly formulation is approved.
Alkem Launches NeuCeno for Partial-Onset Seizures
The Story:
Alkem Laboratories has launched NeuCeno (cenobamate), India’s first cenobamate therapy for adults with partial-onset seizures, as a once-daily oral treatment.
The Take:
The launch strengthens Alkem’s neurology portfolio and adds a new treatment option for patients with uncontrolled focal seizures.
Dr. Reddy’s Launches Nivolumab Biosimilar in India
The Story:
Dr. Reddy’s has launched Nivorz, a biosimilar of Bristol Myers Squibb’s nivolumab, approved for 12 cancer indications in India.
The Take:
The launch marks Dr. Reddy’s entry into India’s biosimilar immuno-oncology segment and expands its oncology portfolio with a lower-cost immunotherapy option.
Gland Pharma to Acquire Gland Pharma USA
The Story:Gland Pharma will acquire 100% of Gland Pharma USA from its Singapore subsidiary for approximately $501,208, making the U.S. entity a direct wholly owned subsidiary.
The Take:The internal restructuring removes a corporate layer and simplifies Gland Pharma’s U.S. operations, oversight and reporting.
